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Abstract
Background: Venous thromboembolism (VTE), comprising deep vein thrombosis (DVT) and pulmonary embolism (PE), is a
significant source of mortality and morbidity worldwide. By analyzing data of the 2010 Nationwide Inpatient Sample from
the Agency for Healthcare Research and Quality (AHRQ), we evaluated the predictive accuracy of the AHRQ’s 29-
comorbidity index with in-hospital death among US adult hospitalizations with a diagnosis of VTE.
Methods: We assessed the case-fatality and prevalence of comorbidities among a sample of 153,518 adult hospitalizations
with a diagnosis of VTE that comprised 87,605 DVTs and 65,913 PEs (with and without DVT). We estimated adjusted odds
ratios and 95% confidence intervals with multivariable logistic regression models by using comorbidities as predictors and
status of in-hospital death as an outcome variable. We assessed the c-statistics for the predictive accuracy of the logistic
regression models.
Results: In 2010, approximately 41,944 in-hospital deaths (20,212 with DVT and 21,732 with PE) occurred among 770,137
hospitalizations with a diagnosis of VTE. When compared separately to hospitalizations with VTE, DVT, or PE that had no
corresponding comorbidities, congestive heart failure, chronic pulmonary disease, coagulopathy, liver disease, lymphoma,
fluid and electrolyte disorders, metastatic cancer, other neurological disorders, peripheral vascular disorders, pulmonary
circulation disorders, renal failure, solid tumor without metastasis, and weight loss were positively and independently
associated with 10%2125% increased likelihoods of in-hospital death. The c-statistic values ranged from 0.776 to 0.802.
Conclusion: The results of this study indicated that comorbidity was associated independently with risk of death among
hospitalizations with VTE and among hospitalizations with DVT or PE. The AHRQ 29-comorbidity index provides acceptable
to excellent predictive accuracy for in-hospital deaths among adult hospitalizations with VTE and among those with DVT or
PE.
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Introduction
Venous thromboembolism (VTE), comprising deep vein
thrombosis (DVT) and pulmonary embolism (PE), is a significant
source of mortality, morbidity, and impaired health-related quality
of life worldwide [1–4]. The 2008 Surgeon General’s Call to Action to
Prevent Deep Vein Thrombosis and Pulmonary Embolism suggested that
VTE might be responsible for approximately 100,0002180,000
deaths per year in the United States [5]. Each year in the United
States, there are more than a half-million adult hospitalizations
with a diagnosis of VTE [6]. Available evidence suggests that a
substantial portion of VTE events also occur among outpatients.
Spencer et al. found 74% of patients with a confirmed episode of
VTE had developed VTE in the outpatient setting [7]. However,
more than a third of these outpatients with VTE might have had
recent hospitalizations [7]. Furthermore, many deaths among
hospitalizations with VTE might be attributable to concurrent
VTE and other health conditions [8,9]. Research has demon-
strated that comorbidities can affect one or more diseases through
several potential etiological mechanisms of direct causation,
associated risk factors, heterogeneity, and independence [10].
Particularly among patients with VTE, the presence of comor-
bidities can hinder clinical assessment and timely diagnoses [11–
13] and exacerbate the risk of recurrence, complications, and
death [14–17].
Comorbidity indices are important tools to characterize disease
burden and complexity, and to identify the prognostic factors that
are essential for clinical assessments and decision-making [10,18–
20]. In observational studies that investigate the relationship
between risk factors and health outcomes of interest, comorbidity
indices frequently are used as a risk-adjustment to control for
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potential confounders [18]. Because the performance of individual
comorbidity indices can vary, researchers often validate applicable
indices by determining their ability to predict specific health
outcomes, such as death among a target patient population [21–
23]. Presently, surprisingly little research has been conducted to
evaluate the performance of comorbidity indices for predicting
death among patients with VTE. The Elixhauser Comorbidity
Index, first reported in 1998, has been used increasingly in
research with administrative data [24–26]. Although the original
Elixhauser Comorbidity Index comprised 30 comorbidities based
on the International Classification of Diseases, Ninth Revision, Clinical
Modification (ICD-9-CM) coding algorithms for diagnoses and
diagnosis-related groups, the Agency for Healthcare Research
and Quality’s (AHRQ) Nationwide Inpatient Sample (NIS)
included 29 of these comorbidity variables after excluding cardiac
arrhythmias due to concerns about reliability [27–29]. To the best
of our knowledge, the performance of the AHRQ 29-comorbidity
index for predicting in-hospital death in adult hospitalizations in
the United States with a diagnosis of VTE and among those with a
diagnosis of DVT or PE has not been validated. Therefore, we
sought to evaluate the predictive accuracy of the AHRQ 29-
comorbidity index for in-hospital death among US adult
hospitalizations with a diagnosis of VTE and among hospitaliza-




All procedures involving human participants and confidentiality
were reviewed and approved by the Research Ethics Review
Board of the AHRQ. Analysis of deidentified data from the NIS is
exempt from the federal regulations for the protection of human
research participants. The NIS is part of the Healthcare Cost and
Utilization Project supported by the AHRQ. It is the largest all-
payer inpatient care database in the United States with 528
million annual unweighted hospitalizations of patients covered by
Medicare, Medicaid, or private insurance, and the uninsured from
about 1,000 community hospitals. The NIS sampling frame
consists of non-federal, short-term, general and specialty hospitals,
and long-term acute care facilities. Excluded from the NIS are
short-term rehabilitation hospitals, long-term non-acute care
hospitals, psychiatric hospitals, and alcoholism or chemical
dependency treatment facilities. The 2010 inpatient core file
contained data for 7,800,441 hospitalizations drawn from 1,051
hospitals of participating states that make up 96% of the US
population. The NIS is designed to approximate a 20% stratified
sample of U.S. community hospitals that include all hospitaliza-
tions in sampled hospitals [30]. Details about the sampling
methodology are described elsewhere [30].
Sample of Hospitalization
The NIS has a maximum of 25 diagnostic codes based on the
ICD-9-CM for each sampled hospitalization. VTE was identified
using ICD-9-CM codes 415.1x, 451.1x, 451.2, 451.8x, 451.9,
453.2, 453.4x, 453.8x, and 453.9 in any of the diagnostic fields.
We restricted our analysis to an unweighted sample of hospital-
izations for adults 18 years of age or older with a diagnosis of VTE
(n = 154,785). Studies of comorbidities in adult hospitalizations
often excluded maternal-related hospitalizations, because such
patients were mostly young with low incidence of comorbidities
and VTE and with a small risk of dying during hospital stay, even
though the risk of developing VTE might be elevated during
pregnancy and postpartum period [28,31–33]. Therefore, after
excluding hospitalizations due to pregnancy, childbirth, and
puerperium and variables with missing information for sex, vital
status, length of hospital stay, or status of primary expected payer,
153,518 unweighted hospitalizations with a diagnosis of VTE were
included as the analytic sample, which comprised 87,605
hospitalizations with a DVT (DVT only) diagnosis and 65,913
hospitalizations with a PE (PE with and PE without DVT)
diagnosis as separate subgroups. Hereinafter, subgroup of PE with
or without DVT will be described as subgroup of PE.
Demographic, Clinical, and Insurance Characteristics
The demographic variables included age, sex, and race or
ethnicity (10.7% unstated). In addition, we included clinical
characteristics and insurance status (i.e., total days of hospital stay,
insurance status of primary expected payer, and status of operating
room procedure) as covariates, because of their relevance to the
outcome and prevention of VTE. All ICD-9-CM procedure codes
in the NIS are assigned to one of four broad categories of minor
diagnostic, minor therapeutic, major diagnostic, and major
therapeutic procedures according to the AHRQ Procedure Classes
[34]. An operating room procedure is defined as having at least
one major diagnostic or major therapeutic procedure during
hospitalization [35].
AHRQ 29-Comorbidity Index
The 29 comorbidities of the NIS are considered as coexisting
medical conditions that are not directly related to the principal
diagnosis or the main reason for admission, and are likely to have
existed prior to the hospital stay [27]. Each of the 29 comorbidities
is based on a unique set of ICD-9-CM codes. Because the
calculation of the category of pulmonary circulation disorders by
the NIS comorbidity software (v3.7) included codes for PE as well
as codes for other diseases in the category (e.g., pulmonary
hypertension), we classified those hospitalizations with PE and
without other disease in the category as having negative
comorbidity status for pulmonary circulation disorders.
Statistical Analysis
For adult hospitalizations with a diagnosis of VTE and
hospitalizations with a diagnosis of DVT or PE, we estimated
the number of in-hospital deaths and case-fatality rates that were
stratified by age, sex, race/ethnicity, total days of hospital stay,
insurance status of primary expected payer, status of operating
room procedure, and number of comorbidities. In addition, we
calculated the percentage distributions of in-hospital deaths by the
number of comorbidities (each comorbidity was counted as 1) and
assessed the prevalence of each of the 29 comorbidities for these
three groups of hospitalizations. To determine the comorbidities
that were associated independently with in-hospital death, we used
a backward elimination procedure of stepwise regression to
remove any explanatory variable with the highest P$0.05 for
individual t-test of null hypothesis b= 0. We repeated the same
procedure until P,0.05 for all explanatory variables in the final
model. Adjusted odds ratios (aORs) and 95% confidence intervals
(CIs) for in-hospital death were generated by using multivariable
logistic regression models to measure independent associations
between remaining comorbidities and in-hospital death while
controlling for age, sex, race or ethnicity, total days of hospital
stay, insurance status of primary expected payer, and status of
operating room procedure. The concordance statistic (or c-
statistic), equivalent to the area under the receiver operating
characteristic (ROC) curve, was calculated to assess the perfor-
mance or discriminative power of logistic regression models in
predicting death [36–38]. Compared to a randomly selected
29-Comorbidity Index for Predicting Death in VTE
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subject (i.e., hospitalization of patient) without the outcome (i.e.,
in-hospital death), the c-statistic was the probability that a
randomly selected subject with the outcome correctly had been
assigned a higher predicted probability of death by logistic
regression model [37,38]. In other words, among all possible
pairs of hospitalizations consisting of one with the outcome (i.e., in-
hospital death) and the other without the outcome, the c-statistic
was the proportion of such pairs in which the hospitalization with
the outcome received a higher predicted probability of death from
the logistic regression model when compared with the hospital-
ization without the outcome [37]. The values of c-statistic can
range from 0.5 (chance) to 1 (perfect). The values of 0.7 to ,0.8,
0.8 to ,0.9, and $0.9 indicate acceptable, excellent, and
outstanding predictive accuracy, respectively [36]. The values of
c-statistic were obtained from logistic regression and the ROC
models that accounted for the sampling weights, stratification, and
clustering of survey data by using the bootstrap replication
estimation. We performed the data management and analysis
using SPSS 21 Complex Samples for Survey Analysis (IBM Corp)
and STATA 11 (StataCorp LP). Unless otherwise noted as an
unweighted sample size (n), all estimates were weighted to account
for the complex sampling design.
Results
We found that a total of 41,944 in-hospital deaths occurred
among 770,137 hospitalizations with a diagnosis of VTE in 2010,
comprising 20,212 deaths among 440,151 hospitalizations with
DVT and 21,732 deaths among 329,986 hospitalizations with PE.
Correspondingly, the case-fatality rates were 5.4% for hospital-
izations with VTE, and 4.6% and 6.6% for hospitalizations with
DVT and PE, respectively. The case-fatality rates varied
significantly by age, sex, race or ethnicity, total days of hospital
stay, insurance status of primary expected payer, status of
operating room procedure, and number of comorbidities
(P,0.05) (Table 1). High case-fatality rates were observed among
subgroups in which patients were 80 years of age or older, were
male, were other race or ethnicity (included categories of ‘‘Asian or
Pacific Islander,’’ ‘‘Native American,’’ and ‘‘other race/ethnici-
ty’’), had a hospital stay of at least 7 days, had Medicare as primary
expected payer, had a ‘‘non-operating room procedure’’ and had
at least five comorbidities (Table 1). While as many as 69.2% in-
hospital deaths with a diagnosis of VTE had at least three
comorbidities and 32.6% in-hospital deaths with a diagnosis of
VTE had at least five comorbidities, similar proportions of
distribution were found for in-hospital with DVT or PE (Figure 1).
After adjusting for covariates including age, sex, race or
ethnicity, total days of hospital stay, insurance status of primary
expected payer, status of operating room procedure, and retained
comorbidities, we found 13 of the AHRQ 29 comorbidities to be
associated significantly and positively with in-hospital death
among either hospitalizations with a diagnosis of VTE or among
hospitalizations with a diagnosis of DVT or PE (Table 2). For
example, in three separate regression models, when compared to
the respective groups of hospitalizations with a diagnosis of VTE,
DVT or PE that had no corresponding comorbidities, congestive
heart failure, coagulopathy, liver disease, fluid and electrolyte
disorders, metastatic cancer, peripheral vascular disorders, renal
failure, solid tumor without metastasis, and weight loss were
positively and independently associated with increased likelihoods
Figure 1. Estimated percentage distribution of in-hospital deaths with a diagnosis of VTE and among those with DVT or PE by
number of comorbidity, NIS, 2010.
doi:10.1371/journal.pone.0070061.g001
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of death (aORs) ranging from 1.3 (95% CI: 1.221.4) to 2.3 (95%
CI: 2.122.4) times. In addition, chronic pulmonary disease was
associated positively and independently with death in hospitaliza-
tions with VTE (aOR = 1.1; 95% CI: 1.021.2) or DVT
(aOR = 1.2; 95% CI: 1.121.3); lymphoma and pulmonary
circulation disorders were associated positively and independently
with death in hospitalizations with VTE (aOR = 1.3; 95% CI:
1.221.5 and aOR = 1.2; 95% CI: 1.121.3, respectively) or in
hospitalizations with a DVT (aOR = 1.6; 95% CI: 1.321.9 and
aOR = 1.3; 95% CI: 1.121.6, respectively). Other neurological
Table 1. Case-fatality rates for in-hospital death among adult hospitalizations with a diagnosis of VTE and among those with DVT
or PE by demographic and clinical characteristics, NIS, 2010.
Characteristics Case-fatality rate for in-hospital death
VTE
(n = 153,518; N = 770,137)
DVTa
(n = 87,605; N = 440,151)c
PEb
(n = 65,913;N = 329,986)
n % CId Pe % CI P % CI P
Overall 153,518 5.4 5.225.7 4.6 4.324.9 6.6 6.326.9
Age ,0.001 ,0.001 ,0.001
18249 33,054 2.6 2.422.9 1.9 1.722.2 3.5 3.123.9
50279 88,128 5.8 5.526.0 4.9 4.625.3 6.8 6.527.1
$80 32,336 7.5 7.128.0 6.2 5.726.7 9.8 9.2210.4
Sex = 0.001 = 0.049 ,0.001
Male 73,592 5.6 5.425.9 4.7 4.425.1 6.9 6.527.2
Female 79,926 5.3 5.025.5 4.5 4.224.8 6.3 6.026.7
Race/ethnicityf ,0.001 = 0.005 ,0.001
White 97,298 5.5 5.325.7 4.7 4.425.0 6.5 6.226.8
Black 24,849 5.5 5.126.0 4.3 3.924.8 7.3 6.727.9
Hispanic 9,313 5.4 4.826.2 4.4 3.725.2 7.5 6.428.7
Otherg 5,646 7.1 6.428.0 6.1 5.227.2 8.9 7.7210.2
Not stated 16,412 4.4 3.725.2 3.8 3.124.7 5.1 4.425.8
Total days of hospital stay ,0.001 ,0.001 ,0.001
,7 days 84,605 4.1 3.924.3 2.5 2.422.7 5.9 5.626.2
$7 days 68,913 7.1 6.727.4 6.8 6.327.2 7.6 7.128.0
Primary expected payer ,0.001 ,0.001 ,0.001
Medicare 83,502 6.5 6.226.8 5.5 5.125.8 8.0 7.628.4
Medicaid 16,014 4.7 4.325.2 3.6 3.224.1 6.4 5.727.1
Private including HMO 41,706 4.0 3.724.3 3.4 3.123.8 4.5 4.224.9
Self-pay or other payers 12,296 4.4 4.024.8 3.3 2.923.8 5.7 5.026.5
Operating room procedure ,0.001 ,0.001 ,0.001
No procedure of any kind 60,751 1.8 1.621.9 1.4 1.221.5 2.2 2.022.4
Non-operating room procedureh 50,369 9.1 8.729.5 7.2 6.827.7 12.0 11.3212.7
Operating room procedurei 42,398 6.3 6.026.7 5.3 4.925.7 8.1 7.528.6
Number of comorbiditiesj ,0.001 ,0.001 ,0.001
0 10,540 1.5 1.321.8 1.6 1.322.0 1.4 1.121.8
1 22,757 2.9 2.623.2 2.4 2.122.7 3.6 3.124.2
2 30,779 4.1 3.824.4 3.4 3.023.8 4.9 4.525.4
3 30,547 4.9 4.625.3 4.1 3.724.4 6.1 5.626.6
4 24,421 6.5 6.126.9 5.7 5.226.2 7.4 6.828.0
$5 34,474 9.3 8.829.8 8.0 7.428.7 10.9 10.3211.5
aWith a diagnosis of DVT only (without a diagnosis of PE).
bWith a diagnosis PE regardless of DVT status.
cn = maximum unweighted subgroup size; N = Weighted population estimate.
d95% confidence interval.
eP-value for Pearson Chi-Square test.
fMay not be nationally representative because not all participating states collect race/ethnicity information.
gIncludes categories of ‘‘other race/ethnicity,’’ ‘‘Native American,’’ and ‘‘Asian or Pacific Islander.’’
hHad at least one minor diagnostic or minor therapeutic procedure (without any major diagnostic or major therapeutic procedure) during hospitalization.
iHad at least one major diagnostic or major therapeutic procedure during hospitalization.
jAHRQ 29-comorbidity index.
doi:10.1371/journal.pone.0070061.t001
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disorders also was associated positively and independently with
death in hospitalizations with PE (aOR = 1.2; 95% CI: 1.021.3)
(Table 2). The distribution patterns of the prevalence for having
each of the 13 comorbidities in hospitalizations were similar across
the three groups of hospitalizations with VTE, DVT, or PE and
ranged from 1.4% for lymphoma to 31.9% for fluid and electrolyte
disorder (Table 2). The c-statistic values that obtained from
adjusted logistic regression and the ROC models ranged from
0.776 to 0.802. Whereas the c-statistic value obtained from logistic
regression models with significant comorbidities suggested an
excellent predictive accuracy for in-hospital death among hospi-
talizations with DVT, the values generally indicated an acceptable
predictive accuracy for in-hospital death among hospitalizations
with VTE and among hospitalizations with DVT (full model) or
PE (Table 3).
Discussion
By using a large, nationally representative sample, we observed
that the AHRQ 29-comorbidity index has acceptable to excellent
predictive accuracy for predicting death among hospitalizations
with VTE and among hospitalizations with DVT or PE.
Regardless of the diagnosis of DVT or PE, we found that 13
comorbidities2congestive heart failure, chronic pulmonary dis-
ease, coagulopathy, liver disease, lymphoma, fluid and electrolyte
disorders, metastatic cancer, other neurological disorders, periph-
eral vascular disorders, pulmonary circulation disorders, renal
failure, solid tumor without metastasis, and weight loss2each were
associated independently with 10%2125% increased risk of in-
hospital death. The predictive accuracy of the 29-comorbidity
index and several nationally representative estimates from this
study (e.g., the estimated number of deaths in hospitalizations with
VTE and in hospitalizations with DVT or PE) have not been
reported in the past.
The results of our study have a number of important implications
for clinical and public health practice. First, health outcome such as
mortality differs among patients and partly depends on their
comorbidity status. Using the AHRQ 29-comorbidity index, our
study provides several nationally representative estimates of
Table 3. Predictive accuracy of AHRQ 29-comorbidity index
for in-hospital death among adult hospitalizations with a
diagnosis of VTE and among those with DVT or PE, NIS, 2010.
n Comorbiditya C-statisticb 95% CIc
VTE n = 153,518
All 29 comorbidities 0.785 0.7792 0.791
Selected comorbidities 0.785 0.7792 0.791
DVT n = 87,605
All 29 comorbidities 0.779 0.77120.787
Selected comorbiditiesd 0.802 0.79320.811
PE n = 65,913
All 29 comorbidities 0.776 0.77120.781
Selected comorbidities 0.785 0.77720.792
aComorbidity retained in logistic regression model that also adjusted for age
(continuous), sex, race/ethnicity, total days of hospital stay (continuous),
primary expected payer, major operating room procedure.
bFrom logistic regression and ROC models with bootstrap replication
estimation.
c95% confidence interval.
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mortality predictors that can aid in the counseling of patients with
VTE and their families thereby contributing to evidence-based
personalized prevention among high-risk patients. Second, in
hospitalizations with VTE and hospitalizations with DVT or PE,
the predictive accuracy remained similar, although we adjusted for
only the 13 comorbidities that were associated positively and
significantly with in-hospital death. Therefore, practitioners ought
to be vigilant in assessing and identifying patients with VTE who
have such comorbidities that might predispose them to heightened
risks of death. Additionally, the potential clinical utilities of the 13
comorbidities as prognostic indicators for VTE may be further
explored and developed in future research. Third, although the
case-fatality rate for PE was higher than for DVT, the overall
mortality burden related to hospitalizations with DVT (accounting
for 20,212 deaths) was similar to those with PE (accounting for
21,732 deaths) in 2010, since the estimated number of hospitaliza-
tions with DVT was larger than that of hospitalizations with PE.
Similarly for those deaths with DVT or PE, we found that a vast
majority (about 7 in 10) of deaths with VTE had at least 3 other
diseases concurrently. Given that major illnesses are associated with
an increased risk of VTE in patients especially during times of
immobilization [39], and that the presence of comorbidities is
associated with a high-risk of death among hospitalizations with
VTE, hospitalized patients with VTE affected by comorbidities are
an important clinical and public health concern. Finally, besides
being associated with worse health outcomes and complex clinical
management, comorbidities potentially can alter both the efficacy of
therapies and the course of the primary disease. With a growing
population of aging adults in the United States, more research and
clinical studies are needed that include patients with various,
significant comorbidities so that optimal prevention strategies can
be developed and intervention results can be extrapolated effectively
for patients with VTE who have similar risk profiles.
Our study results were consistent with those of earlier studies
that reported some comorbidities (e.g., congestive heart failure,
liver disease, lymphoma, metastatic cancer, and renal failure) were
associated independently with an increased risk of death among
the general adult hospitalized populations [40]. Also consistent
with findings of earlier studies, our study findings revealed that
other comorbidities (e.g., anemia, depression, hypertension,
obesity, and valvular disease) were associated with a decreased
risk of in-hospital death which might reflect less urgent overall
conditions of these patients [28,40,41]. On average, patients with
Medicare as primary expected payer insurance were typically
older than those with other types of health insurance. Not
surprisingly, we observed a higher case-fatality rate in hospital-
izations of patients with Medicare than that in subgroups with
other types of health insurance. However, the exact reason for a
lower case-fatality rate in hospitalization with ‘‘operating room
procedure’’ than that with ‘‘non-operating room procedure’’
remained unknown, further research is needed to identify potential
diagnostic and therapeutic procedures (e.g., venous catheterization
and anticoagulation) or their associated conditions that may be
responsible for an increased risk of in-hospital death. Nevertheless,
our study was not without limitations. For instance, our findings
were dependent on the accuracy of collected data (e.g., ICD-9-CM
codes). Due to the incomplete reporting of race or ethnicity
information by some states and potential misclassification, national
estimates for race or ethnicity should be interpreted with caution.
Because of the availability of data elements in the administrative
datasets, we might not have controlled for all possible risk factors
(e.g., anticoagulation) that otherwise might have affected the short-
term risk of death during hospitalizations. Moreover, the NIS
hospitalizations rates did not necessarily reflect rates per patient, as
multiple hospitalizations of the same patients could have been
included. Finally, the cross-sectional study design did not infer a
causal relationship between risk factors and in-hospital death.
Nevertheless, previous research suggested ICD-9-CM codes for
VTE had 95% and 75% positive predictive values for the primary
and secondary positions of diagnosis, respectively [42].
Comorbidity indices are useful for developing predictive models
that can help clinicians to assess and identify high-risk patient
populations, although they have not been adopted to predict the
risk of individual patients. Currently, clinical information of
patients is collected routinely in healthcare settings and yet clinical
data are not always readily available to researchers and
practitioners for instantaneous analysis, interpretation, and
reporting. Additional research still is needed to explore, assess,
develop, and integrate clinical and administrative data for real-
time risk prediction and decision-support that might improve
coordination, enhance evidence-based decision making, increase
compliance, and achieve better health outcomes in healthcare
systems. In conclusion, our results indicated that comorbidity was
associated independently with risk of death among hospitalizations
with VTE and among hospitalizations with DVT or PE. The
AHRQ 29-comorbidity index provides acceptable to excellent
predictive accuracy for in-hospital deaths among adult hospital-
izations with VTE and among those with DVT or PE.
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